Vitamin D antagonizes negative effects of preeclampsia on fetal endothelial colony forming cell number and function by Von Versen-Höynck, F et al.
Vitamin D Antagonizes Negative Effects of Preeclampsia
on Fetal Endothelial Colony Forming Cell Number and
Function
Frauke von Versen-Ho¨ynck1., Lars Brodowski1., Ralf Dechend2, Ashley C. Myerski3, Carl A. Hubel3*
1Department of Obstetrics and Gynecology, Gynecology Research Unit, Hannover Medical School, Hannover, Germany, 2 Experimental and Clinical Research Center (Max-
Delbru¨ck Center for Molecular Medicine and Medical Faculty of the Charite´ and Franz-Volhard Clinic), Helios Klinikum Berlin-Buch, Berlin, Germany, 3Magee-Womens
Research Institute and Department of Obstetrics, Gynecology & Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United
States of America
Abstract
Context: Endothelial dysfunction is a primary feature of preeclampsia, a pregnancy complication associated with an
increased future cardiovascular risk for mother and offspring. Endothelial colony forming cells (ECFC) are endothelial
progenitor cells that participate in vasculogenesis and endothelial repair.
Objective: We hypothesized that the number and functional properties of fetal cord blood-derived ECFCs are reduced in
preeclampsia compared to uncomplicated pregnancy (controls), and asked if adverse effects of preeclampsia on ECFC
function are reversed by 1,25 (OH)2 vitamin D3.
Design, Setting, Patients: This was a nested, case-control study. Forty women with uncomplicated pregnancy and 33
women with PE were recruited at Magee-Womens Hospital (USA) or at Hannover Medical School (Germany).
Main Outcome Measures: Time to ECFC colony appearance in culture, and number of colonies formed, were determined.
Functional abilities of ECFCs were assessed in vitro by tubule formation in Matrigel assay, migration, and proliferation. ECFC
function was tested in the presence or absence of 1,25 (OH)2 vitamin D3, and after vitamin D receptor (VDR) or VEGF
signaling blockade.
Results: The number of cord ECFC colonies was lower (P = 0.04) in preeclampsia compared to controls. ECFCs from
preeclampsia showed reduced proliferation (P,0.0001), formed fewer tubules (P = 0.02), and migrated less (P = 0.049) than
control. Vitamin D3 significantly improved preeclampsia ECFC functional properties. VDR- or VEGF blockade reduced tubule
formation, partially restorable by vitamin D3.
Conclusion: Fetal ECFCs from preeclamptic pregnancies are reduced in number and dysfunctional. Vitamin D3 had rescuing
effects. This may have implications for the increased cardiovascular risk associated with preeclampsia.
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Introduction
Impaired placentation and maternal endothelial dysfunction are
principal features of the pregnancy syndrome preeclampsia (PE)
that affects 3–7% of all pregnancies [1,2]. Effective preventive or
therapeutic strategies do not exist to date [3]. PE has long-term,
adverse health implications for both mother and offspring,
including the development of hypertension and cardiovascular
disease [4,5]. However, the mechanisms linking an abnormal
intrauterine environment to long-term endothelial dysfunction and
vascular damage remain elusive.
Circulating endothelial progenitor cells (EPCs) are critical for
blood vessel formation and repair [6]. EPC numbers and function
inversely correlate with the risk of developing cardiovascular
disease [7]. Based on these characteristics EPCs have been
intensively studied in the context of cardiovascular risk [8].
Endothelial colony forming cells (ECFCs) are a well-defined
subpopulation of EPCs. Unlike other EPC sub-types, they are
directly involved in vasculogenesis and vascularization by popu-
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lating the endothelial surface. They are involved in feto-placental
vasculogenesis [9], which is disturbed in women with PE [10].
Although there is evidence that maternal and fetal (umbilical cord)
circulating EPCs of hematopoietic lineage are reduced in number
and function during PE [11,12,13], data on ECFCs are presently
rare.
Vitamin D3 deficiency is associated with cardiovascular disease,
hypertension, obesity, diabetes mellitus and metabolic syndrome
[14,15]. Compared with uncomplicated pregnancies, PE is
characterized by marked changes in vitamin D3 and calcium
metabolism [16]. A recent meta-analysis and several observational
studies show a significant relationship between vitamin D
deficiency and an increased risk for PE [17,18,19]. Moreover,
PE is associated with a reduced placental and fetal vitamin D pool
[20]. We recently showed a significant promotion of in vitro
angiogenesis by 1,25 (OH)2 vitamin D3 in fetal ECFCs, related to
an increase in VEGF expression and pro-MMP-2 activity,
suggesting a regulatory role of vitamin D for ECFC function [21].
We hypothesized that cord blood ECFC number/abundance
and in vitro proliferative and vasculogenic capacity would be
reduced in PE compared to uncomplicated pregnancies. We
further sought to determine whether the ECFC angiogenesis-
related functional differences can be neutralized by vitamin D. We
compared the number of ECFC outgrowth colonies arising in
culture according to outcome group. We also compared functional
attributes of PE and uncomplicated pregnancy ECFCs in culture,
namely tubule-like structure formation in Matrigel assay, migra-
tion and proliferation, in the presence and absence of supplemen-
tal vitamin D. Further, we tested effects of vitamin D receptor
(VDR) and vascular endothelial growth factor (VEGF) receptor
protein tyrosine kinase 1/2 blockers on tubule formation capacity
of PE and uncomplicated pregnancy ECFCs in the presence and
absence of vitamin D.
Materials and Methods
Patients
This was a collaborative study by members of Magee-Womens
Research Institute (MWRI) and Hannover Medical School
(MHH). The University of Pittsburgh Institutional Review Board
and the Ethical Committee at MHH approved the study.
Informed written consent was obtained from each patient. ECFCs
were isolated from cord blood of 40 uncomplicated (MWRI: 36;
MHH: 4) and 33 PE pregnancies (MWRI: 30; MHH: 3) delivered
by vaginal or Cesarean section (Tables S1 and S2).
PE was diagnosed by the presence of gestational hypertension
and proteinuria beginning after the 20th week of pregnancy, with
resolution of clinical symptoms postpartum. Gestational hyper-
tension was defined as persistent, new onset hypertension (absolute
blood pressure $140 mmHg systolic and/or $90 mmHg diastol-
ic) appearing after 20 weeks of gestation [22]. Proteinuria was
defined as $300 mg per 24-h urine collection, $2+ protein on
voided urine sample, $1+ protein on catheterized urine specimen,
or a protein-creatinine ratio of $0.3. The study subjects were
classified as having an uncomplicated pregnancy if they were
normotensive and without proteinuria throughout gestation, and if
they delivered healthy babies. All women had singleton pregnan-
cies. All patients had no clinical history of preexisting diabetes or
renal, hypertensive or vascular disease, and did not use illicit
drugs.
Pre-pregnancy weight, self-reported at enrollment, and mea-
sured height were used to calculate pre-pregnancy body mass
index (BMI; weight [kg]/height [m2]). Maternal race was by self-
report at enrollment. Self-report, during pregnancy or immedi-
ately postpartum, was used to collect data on tobacco smoking (y/
n). Gestational age-specific birth weight percentiles, adjusted for
infant sex and race, were based upon data from Magee-Womens
Hospital (Pittsburgh, Pennsylvania) or Hannover Medical Center
(Hannover, Germany).
ECFC isolation and culture
ECFCs from cord blood were isolated as previously described
[21]. Briefly, umbilical cord venous blood (15–20 ml) was collected
immediately after delivery into sterile EDTA-coated tubes. Blood
samples were centrifuged within 3 h of collection at 2,000 g for
20 min. Peripheral blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation. The plasma was
removed for collection and replaced with the same volume of
plasma replacement buffer consisting of phosphate buffered saline
solution (PBS) supplemented with 0.025 M EDTA (Sigma Aldrich,
Steinheim, Germany or St. Louis, MO) and 1% (v/v) penicillin/
streptomycin (Sigma Aldrich). The sample volume was doubled by
adding isolation buffer (PBS, 2% (v/v) fetal bovine serum [FBS,
Biochrom KG, Berlin, Germany or Life Technologies, Carlsbad,
CA], 1% penicillin/streptomycin), and the sample was gently
mixed. Samples were layered on Ficoll Plus (GE Healthcare,
Buckinghamshire, England or Piscataway, NJ) and spun at 400 g
for 40 min in a swinging bucket centrifuge with brake in the off
position. The PBMC fraction was collected and washed two times
with isolation buffer. Peripheral blood mononuclear cells were
cultured in endothelial growth medium 2 (EGM-2, Lonza, Basel,
Switzerland or Walkersville, MD), supplemented with supplier-
recommended concentrations of human recombinant epidermal
growth factor, VEGF, ascorbic acid, hydrocortisone, heparin and
recombinant insulin-like growth factor, 10% FBS and 1%
penicillin/streptomycin. The PBMCs were plated at a density of
56107 cells/well on collagen coated 6-well plates (BD Bioscience,
Heidelberg, Germany or Billerica, MA) and incubated at 37uC,
5% CO2. Medium was changed daily for 10 days and then every
second day. First appearance of ECFC colonies was noted as well-
circumscribed monolayers of .50 rapidly proliferating, cobble-
stone-appearing cells. Colonies were identified by visual inspection
using an inverted microscope (Olympus, Tokyo, Japan; Zeiss,
Thornwood, NY). Well- defined colonies were released from the
plates using cloning rings and trypsin-EDTA and collected. The
cells from each separate colony were placed into a well of a
collagen-coated 6 well plate and after becoming 80–90%
confluent, subsequently passaged into collagen-coated T25 culture
flasks. After becoming 80–90% confluent, the cells in the T25
flasks were passaged into gelatin-coated T75s. At 80–90%
confluence these cells were harvested and frozen in freezing
medium containing 92% FCS and 8% DMSO (Sigma Aldrich,
Steinheim, Germany). All experiments were run with ECFCs in
passage 5. ECFCs obtained from cryovials were re-thawed within
3 min in warm water bath and seeded into 75 cm2 tissue culture
flasks and used at 80–90% confluence. For each functional
experiment, ECFCs from PE and a corresponding control patient
were run in tandem.
ECFC Characterization
ECFCs were characterized by immunophenotyping and flow
cytometry as described previously [21]. To assess the ability of cells
to take up Dil-acetylated-low-density lipoprotein (Dil-Ac-LDL;
Biomedical Technologies, Stroughton, MA) and fluorescein
isothiocyanate-labeled Ulex europaeus agglutinin I (lectin; Sig-
ma-Aldrich, Steinheim, Germany) attached cells were incubated
with 5 mg/ml Dil-Ac-LDL and incubated for 4 h at 37uC and
permeabilized with Tergitol-type NP-40 for 1 min. Cells were
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fixed with 4% paraformaldehyde for 10 min and counterstained
with 10 mg/ml lectin for 1 h. DAPI (Thermo Scientific, Rockford,
IL) was used for staining nuclei. Double-positive fluorescence cells
for Dil-Ac-LDL (456 nm) and lectin (488 nm) were identified as
differentiating ECFCs using a Leica EL600 fluorescence micro-
scope (Leica Microsystems, Wetzlar, Germany). Flow cytometric
analyses to confirm the ECFCs phenotype were performed using
surface markers CD31, CD34, CD133, VEGFR-2, and CD45 as
well as appropriate isotype controls. Using 5 mM EDTA (in PBS)
cultivated ECFCs were detached from culture plasticware and
0.56106 cells were used per FACS tube and solubilized in FACS
buffer (0.1% BSA and 0.02% sodium azide in DPBS) before Fc-
receptor blocking reagent (Miltenyi, Auburn, CA) was added.
Isotypes or antibodies were added to the preparations, cells got
washed and were analyzed using the BD flow cytometer LSR-II
and Software BD FACSDiva.
VDR silencing
For silencing of the vitamin D receptor (VDR) ECFCs were
transiently transfected with specific VDR small interfering (si)
RNA (VDR silencer validated siRNA, Ambion, AM51331, Life
Technologies, Darmstadt, Germany, 50 nM) or negative siRNA
(Life Technologies, Carlsbad, USA), diluted in EGM +10% (v/v)
FCS without antibiotics and containing Dharmafect 1 transfection
reagent (Dharmacon, Darmstadt, Germany). siRNA transfection
solution was added to ECFCs in a 6-well plate at 80–90%
confluence. After 24 h of incubation the media was replaced with
regular growth medium (EGM-2) and cells were used for further
experiments. Efficiency of transfection was visualized by fluores-
cence staining and the VDR expression was tested by real-time
RT-PCR. We confirmed a mean reduction of 6460.14% after
silencing of the VDR compared to untreated control cells, and no
significant difference between non-targeting siRNA and untreated
control (Figure S1).
In vitro angiogenesis assay
The capacity of ECFCs to form capillary tubule-like networks
was tested by seeding 17,000 cells/well in 96-well plates pre-coated
with 50 mL growth factor reduced Matrigel (BD Biosciences,
Bedford, MA). The cells were incubated for 14 h, with 0 nM
(vehicle), 1 nM or 10 nM of 1,25 (OH)2 vitamin D3 (Sigma
Aldrich, St. Louis, MO), in endothelial basal medium (EBM;
without supplements) containing 0% or 5% v/v FBS. Light
microscopy images were obtained at 2.56 magnification. The
concentrations of 1,25 (OH)2 vitamin D3 were intended to
approximate physiological levels in pregnancy [23,24]. Total
tubule length in each visual field was measured using ImageJ
freeware (NIH Image). Each treatment was done in triplicate wells.
Triplicate data were averaged, and with experimental ‘‘n’’
corresponding to the patient sample evaluated.
Proliferation assay
To determine the proliferative capacity of ECFCs derived from
uncomplicated and PE pregnancies in the presence or absence of
1,25 (OH)2 vitamin D3, 10,000 cells were seeded per well of 24-
well culture plates in EGM supplemented with 8% (v/v) FBS and
1% penicillin/streptomycin. Medium was changed the next day
and cells were incubated with 0 nM (vehicle), 1 nM or 10 nM of
1,25 (OH)2 vitamin D3. After 24 h, 48 h and 72 h of treatment,
the cell number was counted in a Neubauer chamber with 1:2
trypan-blue dilution. Population doubling time was calculated as
following: log2/ (logNt – logNo), t = time period (h), Nt = number
of cells at time t, No = initial cell number.
Migration assay
Cell migration was assessed using a ‘‘scratch wound healing
assay’’ [25]. 80,000 ECFCs/well were seeded on gelatin coated
wells of 24-well culture plates with EGM containing 10% FBS.
When cells reached 70–80% confluence the medium was changed
to EBM (without growth supplements) with 2% FBS and cells were
pre-incubated with 0 nM (vehicle), 1 nM or 10 nM 1,25 (OH)2
vitamin D3 for 24 h. The cell monolayers were then scratched
with a sterile P200 pipette tip. The media was aspirated and
replaced with the same media to remove non-adherent cells. Light
microscopic images were immediately obtained (incubation start
time, 0) and obtained again after 8 h. Non-populated scratch areas
were quantified by ImageJ software, and the percent closure
(percentage of original area occupied at 8 h by cells that had
migrated into the wound area) was calculated. All experiments
were done in quadruplicate wells.
VDR blocking and VEGF pathway inhibition
To test the VDR receptor-dependency of functional effects of
1,25 (OH)2 vitamin D3, we silenced the VDR with siRNA, or
blocked the VDR with the VDR antagonist pyridoxal-5-phosphate
(0.5 mM, Cell Signaling/New England Biolabs, Frankfurt am
Main, Germany) as described previously [21]. We tested effects of
the Flk-1/KDR (VEGF) receptor tyrosine kinase inhibitor
SU5416 (0.5 mM, Sigma Aldrich, Steinheim, Germany). In vitro
Matrigel tube formation assays were performed (as described
above) in presence or absence of 1,25 (OH)2 vitamin D3 (10 nM)
and with or without the VDR or VEGF inhibitor or after silencing
of the VDR.
Statistical analysis
Demographic data are expressed as means and standard
deviation. Experimental data are presented as means and standard
error. Distribution was examined with Kolmogorov- Smirnov test.
Continuous data were compared with ANOVA, Kruskal-Wallis,
unpaired t-test, Mann-Whitney or Wilcoxon-signed rank test, as
appropriate. Categorical variables were compared by Fisher’s
exact test. Data were analyzed with Prism 4 software package
(GraphPad Software Inc., La Jolla, CA). Where specified, to
account for interassay variation, data are given as fold change in
functional variables relative to untreated ECFCs from uncompli-
cated pregnancies or relative to untreated ECFCs from PE
pregnancies.
Results
Patients demographics
The clinical and demographic data for the pregnant women
who provided blood samples for the analysis of ECFC abundance
and colony formation are presented in Table S1. Data describing
the sub-set of patients whose ECFCs were functionally compared,
are given in Table S2. Maternal age, maternal pre-pregnancy
body-mass index, race and parity, and baby gender were not
statistically different between the PE and control groups (Tables S1
and S2). The percentage of women who were delivered by
Cesarean section versus vaginal delivery did not differ by outcome
group. By definition, women with PE had significantly higher
systolic and diastolic blood pressures at delivery compared to the
uncomplicated study group. Patients of the two groups described
in Table S2 were matched by gestational age for the cell culture
experiments. Infant birth weights and birth weight percentiles
were lower in PE compared to controls.
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Morphology and Characterization of ECFCs
ECFC emerged in culture as discrete, late outgrowth colonies
displaying the characteristic cobblestone morphology. Dil-Ac-LDL
uptake and lectin binding were observed in these cells, consistent
with an endothelial phenotype. In addition flow cytometric results
showed that ECFCs through passage 10 were homogenous and
had the typical phenotype of endothelial cells, being CD31+,
CD45-, and CD133-. The expression of CD34 decreased with
increasing culture time becoming negative at passage 10–15 as
described by Fina et al. [26] (data not shown).
Cord blood ECFC colony numbers and time of first
appearance
The number of cord blood ECFC colonies was significantly
decreased in PE compared with controls (mean 6SD number of
colonies per 56107 PBMCs: 2.263.6 (control) vs. 1.061.8 (PE);
P = 0.04 by Mann-Whitney test). Twenty-four of 36 (67%) control
cord blood samples yielded one or more colonies, whereas colonies
manifested from 13 of 30 (43%) of PE samples (P = 0.06). There
was no difference in the number of days until first appearance of
colonies (.50 characteristic cells), (mean 6SD days: 16.965.6
(control) vs. 17.564.2 (PE); p = 0.73). In addition there was no
significant correlation of birth weight percentile and time to
appearance of colonies (r =20.01, P= 0.57 (control); r =20.19,
P = 0.31 (PE)). The demographic data of the patients are depicted
in Table S1.
In vitro angiogenesis
A Matrigel model was used to assess the capacity of ECFCs to
differentiate into tubule-like structures. Figure 1 displays total
tubule lengths per microscopic field, all as percent relative to
untreated, uncomplicated pregnancy ECFCs (control, 100%).
Tubule assemblage by PE-derived ECFCs was markedly impaired
(7267, p = 0.02, unpaired t test) (Figure 1A). The experiments
represented in Figure 1A were performed in the presence of 5%
(v/v) FBS; similar results were obtained in the absence of FBS,
although no significant differences were reached (Figure 1B).
The impact of 1,25(OH)2 vitamin D3 on capillary-tube
formation of control and PE ECFCs was evaluated after 14 h of
incubation, in the absence or presence of 5% FBS and 1,25(OH)2
vitamin D3. Under incubation with 5% FBS, supplementation
with 1 nM (10562, P= 0.01) or 10 nM (108 6 3, P= 0.04)
1,25(OH)2 vitamin D3 resulted in a small but significant increase of
tubules formed by uncomplicated pregnancy ECFCs (data
expressed as percent relative to vitamin D-untreated ECFCs). A
significant stimulatory effect of vitamin D3 was also observed in the
absence of FBS, by 1 nM (11064, P = 0.04) and 10 nM (11467,
P = 0.02) 1,25(OH)2 vitamin D3, respectively. When expressed as
percent relative to vitamin D-untreated PE ECFCs (100%), in 5%
FBS, both 1 nM (11363, P= 0.001) and 10 nM (11967, P= 0.02)
of 1,25(OH)2 vitamin D3 stimulated the formation of tubules by
ECFCs from women with PE. This effect of vitamin D was more
pronounced in culture medium without FBS: 1 nM (12766,
P = 0.004) or 10 nM (13768, P= 0.003) 1,25(OH)2 vitamin D3.
Consequently, both 1 nM (5% FBS: P= 0.08; 0% FBS: P= 0.4)
and 10 nM (5% FBS: P= 0.1; 0% FBS: P= 0.6) 1,25(OH)2
vitamin D3 neutralized the PE vs. uncomplicated pregnancy
differences in the capacity of ECFCs to form tubules.
Migration
With scratch wound area filling expressed as percent relative to
untreated, uncomplicated pregnancy ECFCs (control, 100%), the
migration of PE ECFCs was significantly impaired (6669,
P= 0.04), (Figure 2 A, B). 1,25(OH)2 vitamin D3 improved ECFC
migration in both pregnancy outcome groups. At 1 nM (11868,
P= 0.04) or 10 nM (142624, P= 0.02) the migration of uncom-
plicated pregnancy ECFCs was significantly stimulated. Expressed
as percent relative to untreated PE (100%), migration into the
scratch wound of PE ECFCs was also significantly higher after
treatment with 1 nM (163616, P = 0.01) and 10 nM (188637,
P= 0.02) 1,25(OH)2 vitamin D3. Therefore, vitamin D restored
ECFC migration derived from PE pregnancies such that there was
no significant between-group difference after treatment with 1 nM
(P= 0.4) or 10 nM (P= 0.3) 1,25(OH)2 vitamin D3.
Proliferation
Figure 3 shows the population doubling time of ECFCs, all
expressed relative to untreated, uncomplicated pregnancy ECFCs
(100%). Population doubling time of ECFCs from PE pregnancies
was significantly prolonged compared to uncomplicated pregnan-
cy ECFCs during 72 h of culture (11162, P,0.0001). Concen-
trations of 1 nM (9361, P,0.001) or 10 nM (8961, P,0.0001)
1,25(OH)2 vitamin D3 significantly reduced the doubling time of
uncomplicated pregnancy ECFCs. With data expressed as percent
relative to vitamin D-untreated PE ECFCs (100%), both the 1 nM
(8862, P= 0.002) and 10 nM (8862, P= 0.02) 1,25(OH)2 vitamin
D3 treatments significantly shortened the population doubling
time of PE ECFCs. Group differences in ECFC proliferation were
neutralized by 1 nM 1,25(OH)2 vitamin D3 (P= 0.07). Although
10 nM 1,25(OH)2 vitamin D3 reduced the population doubling
time in both groups, the doubling time remained shorter in
controls (P = 0.01).
VDR blocking and inhibition of VEGF pathway
We silenced the VDR with siRNA or blocked the VDR with the
VDR antagonist pyridoxal-5-phosphate (P5P). To test whether
VEGF signaling could be involved, we pre-treated cells with the
Flk-1/KDR (VEGF) receptor tyrosine kinase inhibitor SU5416.
Tubule lengths per microscopic field in Figure 4 are expressed as
percentage relative to values from untreated, uncomplicated
pregnancy ECFCs, with experiments performed in the presence
of 5% (v/v) FBS. As shown in Figure 4 A, tubule formation by PE
ECFCs was lower than uncomplicated pregnancy ECFCs in the
absence of vitamin D (76613, P= 0.08, n = 4). Treatment with
10 nM vitamin D increased tubule formation in both groups
(uncomplicated pregnancy: 10862, P= 0.03, n= 5; PE: 11463,
P= 0.02, n = 4, (data expressed as percent relative to vitamin D-
untreated uncomplicated pregnancy or PE ECFCs, respectively).
In the absence of vitamin D, treatment with P5P impaired
angiogenesis in both uncomplicated pregnancy (67611, P = 0.048,
n = 5) and PE ECFCs (64610, P= 0.04, n = 4), as did the VEGF
pathway inhibitor SU5416 (uncomplicated pregnancy: 53611,
P= 0.01, n= 5; PE: 48612, P = 0.02, n= 4). In the presence of
10 nM 1,25(OH)2 vitamin D3, the inhibiting effects of P5P on
ECFC tubule formation remained significant but were less
pronounced (uncomplicated pregnancy: 88610, P = 0.04, n= 5;
PE: 9565, P.0.05, n = 4). In the presence of 10 nM 1,25(OH)2
vitamin D3 the inhibitory effects of SU5416 were also partially
reversed (uncomplicated pregnancy: 74612, P= 0.01, n= 5; PE:
75614, P.0.05, n= 4).
VDR knock down by siRNA had a significant suppressive effect
on tube formation of PE ECFCs (6963, P= 0.003, n= 4)
compared to non-targeting (scrambled) siRNA. VDR siRNA also
caused a significant inhibitory effect on tubule formation of
uncomplicated pregnancy ECFCs (7265, P= 0.007, n= 5) com-
pared to non-targeting siRNA. Vitamin D had no effects on tubule
formation after siRNA treatment (Figure 4 B). Tubule formation
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did not differ between non-targeting siRNA and no siRNA
treatments (vehicle), (Figure 4B).
Discussion
Here we have shown differences in number and function of fetal
ECFCs isolated from cord blood of uncomplicated pregnancies
compared to PE pregnancies. The number of ECFC colonies
Figure 1. Effect of preeclampsia (PE) and 1,25(OH)2 vitamin D3 on capillary-tube formation in a Matrigel assay. ECFCs were cultured in
endothelial basal medium (EBM) + 5% FBS (A) or without FBS (B) and treated with 1 nM or 10 nM 1,25(OH)2 vitamin D3 or without vitamin D3. Control:
uncomplicated pregnancy. Capillary-tube formation (average total tubule length per microscopic field) was analyzed after 14 h by visual microscopy
at 2.56 magnification. Data are expressed as percentage of control. Results represent mean values of total tubule length 6SEM of at least 8
independent experiments. *P,0.05 vs. untreated control or (as indicated by horizontal lines above the vertical bars) vs. untreated PE for 1,25(OH)2
vitamin D3 effects. C: Representative photomicrographs of ECFCs in Matrigel assay with EBM +5% FBS. Scale bar represents 750 mm.
doi:10.1371/journal.pone.0098990.g001
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obtained from PE pregnancies was significantly lower, and
functional properties, i.e. proliferation, migration and tubule
formation, were impaired compared to ECFCs from healthy
pregnancies. These effects were largely independent of the FBS
concentration used in the experiments. In the presence of 1,25
(OH)2 vitamin D3, the functional properties improved and the
negative effects of preeclampsia on fetal ECFCs were significantly
lessened. The positive effects of vitamin D were dependent on
VDR activation, as indicated by experiments with either VDR
gene silencing (siRNA) or VDR blockade (pyridoxal-5-phosphate).
The findings suggest that ECFC tubule formation in the presence
of FBS is, at least in part, VDR dependent. The vitamin D
pathway appeared to involve stimulation of the VEGF signaling
cascade, given that SU5416 suppressed ECFC tubule formation in
a fashion similar to VDR blockade. Except for siRNA knockdown
of the VDR these effects were substantially reversed by a co-
treatment with 1,25 (OH)2 vitamin D3. We speculate that a
displacement in form of a competitive antagonism by vitamin D at
the receptor reduced the negative effects of pyridoxal-5-phosphate
and SU5416 on angiogenesis. The reason why inhibition of VDR,
either through pharmacological intervention or siRNA, reduced
tube lengths in the absence of supplemental vitamin D is unknown.
It is possible that vitamin D in fetal bovine serum (FBS) is sufficient
to promote submaximal tubule formation. In our earlier publica-
tion we likewise observed a reduction of ECFC tubule formation in
Matrigel upon inhibition of the VDR with siRNA in the absence
of supplemental vitamin D [21]. In that study we surprisingly
observed that 10 nM 1,25(OH)2 vitamin D in the presence of
VDR siRNA caused a further reduction in tubule formation. We
speculated that the higher levels of vitamin D might exert
inhibitory effects by activating a membrane bound (non-classical)
VDR, when the nuclear VDR is downregulated.
Our findings confirm data of our previous study in which we
demonstrated a stimulating effect of 1,25 (OH)2 vitamin D3 on
fetal ECFC function in uncomplicated pregnancies [21]. To our
knowledge, however, this is the first study to demonstrate
functional deficits of fetal ECFC from pregnancies complicated
by PE compared to uncomplicated pregnancies, and significant
restoration of function by vitamin D.
Endothelial colony forming cells (ECFC) are a subset of
endothelial progenitor cells and critical to blood vessel formation
and repair [6]. Their dysfunction represents a risk factor for
cardiovascular disease [27]. Previous studies of endothelial
progenitor cells with hematopoietic (non-ECFC) characteristics
(CD133+ and/or CD45+) found lower circulating numbers and
reduced colony-forming ability in PE compared to control
Figure 2. Effect of preeclampsia (PE) and 1,25(OH)2 vitamin D3 on ECFC migration. ECFCs of uncomplicated (control) and PE pregnancies
were cultured in endothelial basal medium (EBM) +2% FBS and treated with or without 1 nM or 10 nM 1,25(OH)2 vitamin D3. A: The migration of
ECFCs into the scratch wound was assessed after incubation for 8 h. Results represent mean6SEM percent wound filling, n = 8. *P,0.05 vs. untreated
control or (as indicated by horizontal lines above the vertical bars) vs. untreated PE. B: Representative images of ECFC monolayers with scratch
wounds at 0 h (a, c) and 8 h (b, d) of incubation of control (a, b) and preeclamptic pregnancies (c, d).
doi:10.1371/journal.pone.0098990.g002
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maternal blood samples [12,13]. This implicates a source of
maternal endothelial dysfunction by lessening endothelial repair
and vasculogenic capacity. Due to their rarity in the maternal
compared to fetal circulation, impractically large volumes of
maternal blood ($50 mL) would likely be necessary to obtain
sufficient numbers of maternal blood ECFCs for study [28].
Our unpublished data indicate no effect of 1 or 10 nM
concentrations of 1,25(OH)2 vitamin D on tube formation,
migration or proliferation of human umbilical vein endothelial
cells (HUVEC) in culture. This, combined with several reports
that 1,25(OH)2 vitamin D either decreases or has no effect on
endothelial cell proliferation or angiogenesis in vivo or in vitro
[29,30], might reflect heterogeneity among endothelial cell
subtypes. ECFCs reportedly differ from HUVEC or human
umbilical artery endothelial cells in the expression of differentia-
tion-related surface markers (such as CD44) or activities such as
proliferation or telomerase activities [31]. However the reason for
the distinct proangiogenic response to vitamin D by ECFCs is
presently unclear. Circulating hematopoietic endothelial progen-
itor cells, a more abundant progenitor type compared to ECFCs,
respond to vitamin D and express functional vitamin D receptors.
Interestingly, conditioned media from vitamin D (10 nM) treated
hematopoietic progenitors increased tubule networks of human
aortic endothelial cells in the Matrigel angiogenesis assay, whereas
vitamin D alone did not [32]. To speculate, vitamin D might
upregulate release of angiogenic factors by ECFCs that stimulate
in an autocrine fashion.
Our data are similar in pattern to previous studies that showed a
significantly decreased number of fetal hematopoietic EPCs from
PE compared with those of normal pregnancy [33,34,35].
Moreover, fetal hematopoietic EPCs from preeclamptic women
were more senescent and free VEGF was significantly decreased
compared to controls [33,34]. However, the progenitor cells in the
aforementioned publications fail to form vessels in vivo or in vitro,
and are clonally distinct from ECFCs [36].
Reduced fetal ECFC numbers and colony formation have also
been observed in diabetic or growth restricted (IUGR) pregnan-
cies, suggesting potential mechanistic insights into the long-term
cardiovascular complications observed in newborns [37,38,39]. In
vivo, IUGR ECFCs formed fewer blood vessels and capillaries
compared to normal pregnancy-derived ECFCs. In culture, IUGR
ECFCs showed reduced proliferation and migration abilities
combined with a reduced hypoxia-induced MMP-2 release [38].
However, we found no significant correlation between birth
weight percentile and ECFC variables in either group (data not
shown). Furthermore, when excluding the SGA pregnancies, the
results for tubule formation and population doubling time
Figure 3. Effect of pregnancy outcome and 1,25(OH)2 vitamin
D3 on ECFC population doubling time. ECFCs of uncomplicated
(control) and preeclamptic (PE) pregnancies were incubated in the
presence and absence of 1,25(OH)2 vitamin D3 (1 nM or 10 nM) in EGM
+8% (v/v) FBS. Cell numbers were counted and population doubling
time calculated after 72 h. Population doubling time was significantly
longer in PE ECFCs compared to uncomplicated pregnancy (control) in
the absence of supplemental vitamin D (P,0.05). PE population
doubling time was reduced to control levels by vitamin D, n = 8. *P,
0.05 vs. untreated control or (as indicated by horizontal lines above the
vertical bars) vs. untreated PE for 1,25(OH)2 vitamin D3 effects.
doi:10.1371/journal.pone.0098990.g003
Figure 4. Effect of 1,25(OH)2 vitamin D3 and the inhibitors pyridoxal-5-phosphate, SU5416 and vitamin D receptor (VDR) small
interfering (si)RNA on capillary-tube formation. ECFCs of uncomplicated (control) and preeclamptic (PE) pregnancies were cultured in EBM +
5% (v/v) FBS and treated with 10 nM 1,25(OH)2 vitamin D3 for 14 h. Control: uncomplicated pregnancy. PE: pregnancy complicated by preeclampsia.
Capillary-tube formation was determined by seeding 17,000 ECFCs on 50 ml Matrigel and incubated with 0.5 mM pyridoxal-5-phophate, 0.5 mM
SU5416 (A) or 50 nM VDR siRNA or non-targeting siRNA (B) each either without additional 1,25(OH)2 vitamin D3 or with 10 nM 1,25(OH)2 vitamin D3
treatment respectively. Tubule length was analyzed after 14 h by visual microscopy at 2.56magnification. Results represent mean6SEM of at least 4
independent experiments. *P,0.05 compared to control.
doi:10.1371/journal.pone.0098990.g004
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remained significant despite the reduced sample size (data not
shown). This suggests that group differences were primarily driven
by PE.
EPCs remain difficult to define due to the lack of a specific and
unique cell surface or molecular marker. The ECFCs used in our
study were rigorously identified using a combination of cell surface
markers (CD34+, CD1332, CD452), immunostaining and mor-
phologic measures, e.g. colony-forming ability. Future comparison
of ECFC function and effects of vitamin D in vasculogenic assays
in vivo (e.g. mouse Matrigel plug assay [38]) would be useful.
In summary, this is to our knowledge the first report
demonstrating fetal ECFC dysfunction in preeclampsia, and a
marked improvement of fetal ECFC function with neutralization
of negative effects of preeclamptic pregnancy by 1,25 (OH)2
vitamin D3. There appear to be adverse cardiovascular health
implications, including increased risk of stroke, for adult offspring
of preeclamptic pregnancies [40]. A recent systematic review
concluded that young offspring of preeclamptic pregnancies
already have increased blood pressure and BMI, both risk factors
for future cardiovascular disease [41]. However, currently the
mechanisms underlying these associations remain unclear and
preventive strategies do not exist. It is plausible that avoidance of
hypovitaminosis D could contribute to a reduction in feto-
placental endothelial dysfunction, reduction in adverse pregnancy
outcomes, and possibly have long-term implications for the
cardiovascular health of offspring.
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